RU2007104107A - Тиофлавиновые производные, являющиеся суррогатными маркерами амилоидных отложений (варианты), способ определения эффективности терапевтического лечения амилоидоза (варианты) и способ выявления пациента, находящегося в продромальной стадии заболевания, ассоциированного с отложением амилоида - Google Patents
Тиофлавиновые производные, являющиеся суррогатными маркерами амилоидных отложений (варианты), способ определения эффективности терапевтического лечения амилоидоза (варианты) и способ выявления пациента, находящегося в продромальной стадии заболевания, ассоциированного с отложением амилоида Download PDFInfo
- Publication number
- RU2007104107A RU2007104107A RU2007104107/04A RU2007104107A RU2007104107A RU 2007104107 A RU2007104107 A RU 2007104107A RU 2007104107/04 A RU2007104107/04 A RU 2007104107/04A RU 2007104107 A RU2007104107 A RU 2007104107A RU 2007104107 A RU2007104107 A RU 2007104107A
- Authority
- RU
- Russia
- Prior art keywords
- group
- lower alkyl
- alkyl group
- substituents
- unsubstituted
- Prior art date
Links
- DZAJAJHCKORZOE-UHFFFAOYSA-N CN1CCSN(SC)SCC1 Chemical compound CN1CCSN(SC)SCC1 DZAJAJHCKORZOE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58448704P | 2004-07-02 | 2004-07-02 | |
| US60/584,487 | 2004-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007104107A true RU2007104107A (ru) | 2008-08-10 |
Family
ID=35504952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007104107/04A RU2007104107A (ru) | 2004-07-02 | 2005-07-01 | Тиофлавиновые производные, являющиеся суррогатными маркерами амилоидных отложений (варианты), способ определения эффективности терапевтического лечения амилоидоза (варианты) и способ выявления пациента, находящегося в продромальной стадии заболевания, ассоциированного с отложением амилоида |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8147798B2 (pt-PT) |
| EP (1) | EP1771208B1 (pt-PT) |
| JP (1) | JP2008505115A (pt-PT) |
| CN (2) | CN101137397A (pt-PT) |
| AU (1) | AU2005270026A1 (pt-PT) |
| BR (1) | BRPI0512893B8 (pt-PT) |
| CA (2) | CA2830939C (pt-PT) |
| CY (1) | CY1114644T1 (pt-PT) |
| DK (1) | DK1771208T3 (pt-PT) |
| ES (1) | ES2427963T3 (pt-PT) |
| NO (1) | NO339187B1 (pt-PT) |
| PL (1) | PL1771208T3 (pt-PT) |
| PT (1) | PT1771208E (pt-PT) |
| RU (1) | RU2007104107A (pt-PT) |
| SI (1) | SI1771208T1 (pt-PT) |
| WO (1) | WO2006014381A2 (pt-PT) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
| US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2004069182A2 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
| US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
| WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| GB0516564D0 (en) * | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
| WO2007035405A2 (en) * | 2005-09-16 | 2007-03-29 | University Of Pittsburgh | In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
| TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| CN101293878B (zh) * | 2007-04-25 | 2010-12-15 | 中国科学院上海应用物理研究所 | 苯并噻唑苯胺类化合物及其制备方法和应用 |
| PL2182983T3 (pl) * | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
| WO2009027452A2 (en) * | 2007-08-30 | 2009-03-05 | Ge Healthcare Limited | Radiopharmaceutical composition |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| JP5603855B2 (ja) | 2008-04-04 | 2014-10-08 | アビッド レディオファーマシューティカルズ、インク． | 神経変成疾患の放射性薬剤による画像化 |
| RU2518892C2 (ru) * | 2008-09-23 | 2014-06-10 | Виста Лабораториз Лтд. | Лиганды для агрегированных молекул тау-белка |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2010053218A1 (en) * | 2008-11-06 | 2010-05-14 | Snu R&Db Foundation | Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same |
| JP2013521233A (ja) * | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| WO2014004664A2 (en) * | 2012-06-27 | 2014-01-03 | Mayo Foundation For Medical Education And Research | Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives |
| US9422286B2 (en) | 2014-01-27 | 2016-08-23 | Washington University | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease |
| AU2016308189B2 (en) * | 2015-08-18 | 2021-03-11 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
| PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
| US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| DE60217090T2 (de) * | 2001-04-23 | 2007-07-12 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel |
| GB0130305D0 (en) | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
| JP2005523903A (ja) | 2002-02-13 | 2005-08-11 | アメルシャム・パブリック・リミテッド・カンパニー | アミロイド斑の生体内撮像用のベンゾチアゾール誘導体 |
| CA2438032C (en) | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| GB0307855D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| BRPI0512932A (pt) * | 2004-07-02 | 2008-04-15 | Univ Pittsburgh | compostos e métodos de identificação e de diagnóstico de paciente como prodrÈmico para doença associada com a deposição amilóide |
-
2005
- 2005-07-01 PL PL05787557T patent/PL1771208T3/pl unknown
- 2005-07-01 WO PCT/US2005/023617 patent/WO2006014381A2/en active Application Filing
- 2005-07-01 DK DK05787557.7T patent/DK1771208T3/da active
- 2005-07-01 SI SI200531765T patent/SI1771208T1/sl unknown
- 2005-07-01 ES ES05787557T patent/ES2427963T3/es active Active
- 2005-07-01 CN CNA2005800263010A patent/CN101137397A/zh active Pending
- 2005-07-01 AU AU2005270026A patent/AU2005270026A1/en not_active Abandoned
- 2005-07-01 PT PT57875577T patent/PT1771208E/pt unknown
- 2005-07-01 US US11/666,083 patent/US8147798B2/en active Active
- 2005-07-01 CN CN2012104014697A patent/CN102973954A/zh active Pending
- 2005-07-01 JP JP2007519500A patent/JP2008505115A/ja active Pending
- 2005-07-01 CA CA2830939A patent/CA2830939C/en active Active
- 2005-07-01 EP EP05787557.7A patent/EP1771208B1/en active Active
- 2005-07-01 CA CA2587248A patent/CA2587248C/en active Active
- 2005-07-01 RU RU2007104107/04A patent/RU2007104107A/ru not_active Application Discontinuation
- 2005-07-01 BR BRPI0512893A patent/BRPI0512893B8/pt active IP Right Grant
-
2007
- 2007-01-31 NO NO20070593A patent/NO339187B1/no unknown
-
2012
- 2012-03-06 US US13/412,823 patent/US8343457B2/en active Active
- 2012-10-23 US US13/658,483 patent/US8580229B2/en active Active
-
2013
- 2013-09-10 CY CY20131100776T patent/CY1114644T1/el unknown
- 2013-10-09 US US14/050,018 patent/US20140105820A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1771208T1 (sl) | 2013-10-30 |
| US20130045164A1 (en) | 2013-02-21 |
| NO339187B1 (no) | 2016-11-14 |
| CN102973954A (zh) | 2013-03-20 |
| US20140105820A1 (en) | 2014-04-17 |
| WO2006014381A2 (en) | 2006-02-09 |
| ES2427963T3 (es) | 2013-11-05 |
| CA2587248C (en) | 2014-01-07 |
| EP1771208A2 (en) | 2007-04-11 |
| US8343457B2 (en) | 2013-01-01 |
| BRPI0512893A (pt) | 2008-04-15 |
| US8147798B2 (en) | 2012-04-03 |
| CA2830939C (en) | 2017-02-28 |
| NO20070593L (no) | 2007-03-27 |
| WO2006014381A9 (en) | 2006-04-13 |
| PT1771208E (pt) | 2013-09-24 |
| WO2006014381A3 (en) | 2007-01-18 |
| BRPI0512893B1 (pt) | 2019-12-24 |
| CA2587248A1 (en) | 2006-02-09 |
| DK1771208T3 (da) | 2013-09-02 |
| CA2830939A1 (en) | 2006-02-09 |
| CY1114644T1 (el) | 2016-10-05 |
| PL1771208T3 (pl) | 2013-11-29 |
| AU2005270026A1 (en) | 2006-02-09 |
| US20080219931A1 (en) | 2008-09-11 |
| EP1771208B1 (en) | 2013-06-19 |
| BRPI0512893B8 (pt) | 2021-07-27 |
| US8580229B2 (en) | 2013-11-12 |
| US20120177572A1 (en) | 2012-07-12 |
| JP2008505115A (ja) | 2008-02-21 |
| CN101137397A (zh) | 2008-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007104107A (ru) | Тиофлавиновые производные, являющиеся суррогатными маркерами амилоидных отложений (варианты), способ определения эффективности терапевтического лечения амилоидоза (варианты) и способ выявления пациента, находящегося в продромальной стадии заболевания, ассоциированного с отложением амилоида | |
| RU2007104106A (ru) | Способ выявления пациента, находящегося в продромальной стадии заболевания, ассоциированного с отложением амилоида (варианты), способ диагностики вышеуказанной продромальной стадии и тиофлавиновые производные, являющиеся компонентами диагностикумов вышеуказанной продромальной стадии (варианты) | |
| RU2324686C2 (ru) | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА | |
| JP2012102106A5 (pt-PT) | ||
| TWI245764B (en) | Amyloid plaque aggregation inhibitors and diagnostic imaging agents | |
| JP2004506723A5 (pt-PT) | ||
| TWI568714B (zh) | 用於合成及使用造影劑之組合物、方法及系統 | |
| US20180028694A1 (en) | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | |
| JP2021500373A5 (pt-PT) | ||
| BRPI0617151B8 (pt) | composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico | |
| US6676926B2 (en) | Radiopharmaceuticals for diagnosing Alzheimer's disease | |
| AU2011200667B2 (en) | Benzothiazole derivative compounds, compositions and uses | |
| RU2006107563A (ru) | Зонды для заболеваний с накоплением амилоида, красители для амилоида, лекарства для лечения и профилактики заболеваний с накоплением амилоида, зонды для диагностики нейрофибриллярных клубков и красители для нейрофибриллярных клубков | |
| CN111741751A (zh) | 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途 | |
| RU2008126463A (ru) | Связывающие амилоид бензотиазоловые соединения (варианты), фармацевтическая композиция на их основе, способ детекции отложений амилоида (варианты), способ отличения пораженного болезнью альцгеймера мозга от нормального, способ измерения количества амилоида, способ избирательного связывания с амилоидными бляшками (варианты) и способ выявления продромальной стадии заболевания, связанного с отложениями амилоида с их помощью | |
| EP2501696A2 (en) | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases | |
| RU2009110480A (ru) | Фторсодержащие лиганды для нацеливания периферических бензодиазепиновых рецепторов | |
| US9422286B2 (en) | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease | |
| KR102531494B1 (ko) | 탄산 탈수효소 ix를 표적으로 하는 핵 영상화 및 방사선치료 제제 및 이의 용도 | |
| CA2500358A1 (en) | Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles | |
| JPH04506057A (ja) | 黒色腫の診断および治療薬 | |
| JP6260967B2 (ja) | 放射性ヨウ素標識化合物、及び、これを含む放射性医薬 | |
| JP2013237655A (ja) | コンフォメーション病診断用分子プローブ | |
| JP2002543173A5 (pt-PT) | ||
| RU2019118365A (ru) | Хелатные соединения марганца на основе тетраазабицикло-макроцикла, подходящие в качестве визуализирующих агентов для MRI |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100827 |